Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terbinafine phase 2a trial in chronic hepatitis B
NL-OMON52526Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Terbinafine in Chronic Hepatitis B (CHB) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Serum HBsAg decline at end of treatment and Serum HBV DNA decline in monotherapy group. Started Apr 2022; status: recruiting.
02
Drugs
Terbinafine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON52526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52526.